First Wave Biopharma Stock EBITDA
| FWBIDelisted Stock | USD 0.61 0.03 4.69% |
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
First |
First Wave BioPharma Company EBITDA Analysis
First Wave's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current First Wave EBITDA | (15.74 M) |
Most of First Wave's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, First Wave BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
CompetitionAccording to the company disclosure, First Wave BioPharma reported earnings before interest,tax, depreciation and amortization of (15.74 Million). This is 101.79% lower than that of the Biotechnology sector and 115.72% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.4% higher than that of the company.
First EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.First Wave is currently under evaluation in ebitda category among its peers.
First Fundamentals
| Return On Equity | -0.15 | |||
| Return On Asset | -0.27 | |||
| Current Valuation | 72.56 M | |||
| Shares Outstanding | 2.03 M | |||
| Shares Owned By Insiders | 5.66 % | |||
| Shares Owned By Institutions | 1.46 % | |||
| Number Of Shares Shorted | 46.6 K | |||
| Price To Book | 1.87 X | |||
| EBITDA | (15.74 M) | |||
| Net Income | (15.79 M) | |||
| Cash And Equivalents | 1.16 M | |||
| Cash Per Share | 0.83 X | |||
| Total Debt | 826.84 K | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 0.10 X | |||
| Book Value Per Share | 7.99 X | |||
| Cash Flow From Operations | (12.38 M) | |||
| Short Ratio | 1.02 X | |||
| Earnings Per Share | (47.88) X | |||
| Target Price | 36.0 | |||
| Beta | 1.28 | |||
| Market Capitalization | 5.99 M | |||
| Total Asset | 6.88 M | |||
| Retained Earnings | (184.33 M) | |||
| Working Capital | 1.82 M | |||
| Net Asset | 6.88 M |
About First Wave Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in First Stock
If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |